Auscandoc<p>‘Extremely impressive’: melanoma jab trial results excite doctors <a href="https://www.theguardian.com/society/article/2024/jun/03/extremely-impressive-melanoma-jab-trial-results-excite-doctors?CMP=Share_iOSApp_Other" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://www.</span><span class="ellipsis">theguardian.com/society/articl</span><span class="invisible">e/2024/jun/03/extremely-impressive-melanoma-jab-trial-results-excite-doctors?CMP=Share_iOSApp_Other</span></a> “The world’s first personalised <a href="https://med-mastodon.com/tags/mRNA" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>mRNA</span></a> <a href="https://med-mastodon.com/tags/CancerVaccine" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>CancerVaccine</span></a> for <a href="https://med-mastodon.com/tags/melanoma" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>melanoma</span></a> halves the risk of patients dying or the disease returning, according to trial results that doctors described as “extremely impressive”.</p><p>Patients who received the vaccine after having a stage 3 or 4 melanoma removed had a 49% lower risk of dying or the disease recurring after three years”</p>